Clinical Trials Sponsored by Argo Sante

Total 3240 results

Argon Medical Devices
Avania

Terminated

Achieving Portal Access With Scorpion Post-Approval Study (APASS)

Liver Diseases | Vascular Diseases | Portal Hypertension | Ascites Hepatic | Hydrothorax

United States
Duke University
Argos Therapeutics

Terminated

RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)

Metastatic Renal Cell Carcinoma | Genitourinary Cancer (Bladder, Prostate or Testicular)

United States
Fargo VA Medical Center

Completed

Effect of Lactobacillus Probiotic on Healthy Adults

Antibiotic-associated Diarrhea

United States
Asten Sante

Recruiting

Consequences of Respiratory Devices on Caregivers (CAP2) (CAP2)

Quality of Life

France
AURA Sante

Unknown

Long Term Physical Activity for Hemodialysis Patients

End Stage Renal Disease on Hemodialysis
Argon Medical Devices
NAMSA

Not yet recruiting

CLEANer Aspiration for Pulmonary Embolism (CLEAN-PE)

Cardiovascular Diseases | Venous Thromboembolism | Pulmonary Embolism | Acute Pulmonary Embolism

United States
Arjo AB
Loughborough University

Enrolling by invitation

A Comparison Study of the Maxi Move 5 (MM5) Device

Healthy Volunteers

United Kingdom
AGO Research GmbH

Not yet recruiting

Pembrolizumab in Combination With Lenvatinib in Patients With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy (PIERCE)

Recurrent Vulvar Cancer | Persistent Vulvar Cancer | Metastatic Vulva Cancer | Locally Advanced Vulvar Cancer
AGO Research GmbH

Recruiting

WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC (WoO)

Epithelial Ovarian Cancer

Germany
AGO Research GmbH

Completed

Prevalence of BRCA in Patients With Ovarian Cancer

Ovarian Cancer | BRCA Status

Germany
AGO Study Group

Completed

Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer

Sarcoma | Cervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer

Germany
AGO Study Group

Completed

Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients

Fallopian Tube Neoplasms | Peritoneal Neoplasms | Ovarian Cancer

Germany
AGO Study Group

Terminated

Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum

Anemia | Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum | Platinum Sensitve Relapse

Germany
AGO Study Group

Completed

Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

Germany
AGO Study Group

Completed

A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy

Ovarian Cancer | Peritoneal Cancer | Cancer of the Fallopian Tube

Germany
AGO Study Group

Completed

Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer

Ovarian Cancer
AGO Study Group

Completed

Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response

Fallopian Tube Neoplasms | Peritoneal Neoplasms | Ovarian Cancer

Germany
University of Kentucky
Arno Therapeutics

Completed

A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies

Solid Malignancies

United States
AGO Research GmbH

Recruiting

Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer (MIROVA)

Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma

Germany
AGO Study Group

Active, not recruiting

Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (TRUST)

Ovarian Cancer

United States, France, Germany, Austria, Sweden, Denmark, Italy, United Kingdom
AGO Research GmbH

Terminated

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

Recurrent Ovarian Carcinoma

Germany
AGO Study Group

Completed

Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma

Ovarian Diseases | Ovarian Neoplasms | Endometrial Neoplasms | Genital Diseases, Female

Germany
AGO Study Group

Completed

Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer

Ovarian Cancer | Fallopian Tube Cancer

Germany
AGO Study Group

Completed

Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer

Epithelial Ovarian Cancer

Germany
AGO Study Group

Completed

Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer

Ovarian Cancer

Germany
Xention Ltd
Ario Pharma Ltd

Completed

A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With Chronic Idiopathic Cough

Chronic Idiopathic Cough

United Kingdom, Ireland
Arjo France
Pôle Saint Hélier

Recruiting

Evaluation of the Sub Epidermal Moisture a Device for the Screening of Pressure Ulcer (RELIASEM) (RELIASEM)

Preventive Care

France
Xention Ltd
Ario Pharma Ltd

Completed

A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With COPD

Chronic Obstructive Pulmonary Disease

United Kingdom
Fondation Sante Service

Recruiting

Transverse Study About QOL for Colostomized or Ileostomized Patients During Their Home Hospitalization (STOM'HAD)

Colostomy | Ileostomy | Home Hospitalization

France
Dedienne Sante S.A.S.

Completed

Retrospective Observational Cohort Study of SYMBOL CUP DM 2 (SYMCOR-2)

Primary Total Hip Arthroplasty | Revision Total Hip Arthroplasty

France
Dedienne Sante S.A.S.

Completed

Retrospective Observational Cohort Study of SYMBOL CUP DM 1 (SYMCOR-1)

Primary Total Hip Arthroplasty

France
CEN Biotech
Urgo Research, Innovation & Development

Recruiting

Effectiveness of a Nasal Spray on Viral Respiratory Infections

COVID-19 | Common Cold | Acute Respiratory Tract Infection | Flu, Human

France
Arno Schmidt-Trucksäss

Recruiting

Heart Rate Variability, Physical Activity and Exhaustion in the Inpatient Treatment of Stress-Related Disorders (HARMODI)

Depression | Burnout | Stress Related Disorder

Switzerland
Arno Schmidt-Trucksäss

Recruiting

Sequelae of COVID-19 With Focus on Exercise Capacity and Underlying Mechanisms (COR-PHYS)

Controls | Patients Post-COVID-19

Switzerland
Eli Lilly and Company
ARMO BioSciences

Terminated

Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer (Cypress 1)

Non Small Cell Lung Cancer

United States
Eli Lilly and Company
ARMO BioSciences

Completed

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer (Sequoia)

Pancreatic Cancer

United States, Belgium, Spain, Poland, Korea, Republic of, Taiwan, Germany, Italy, France, United Kingdom, Austria, Australia, Canada
Eli Lilly and Company
ARMO BioSciences

Completed

A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) (Willow 2)

Healthy Adult Subjects

United States
Eli Lilly and Company
ARMO BioSciences

Active, not recruiting

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (IVY)

Melanoma | Renal Cell Carcinoma | Breast Cancer | Ovarian Cancer | Prostate Cancer | Non-small Cell Lung Carcinoma | Solid Tumors | Colorectal Carcinoma | Pancreatic Carcinoma

United States
Arno Schmidt-Trucksäss

Completed

Mini-trampoline Intervention vs. Nordic Walking: Balance, Fitness and Neuropsychological Effects (TraWaFit)

Obesity | Overweight

Switzerland
University Hospital Inselspital, Berne
Arco Foundation

Completed

Effect of Transcutaneous Electrostimulation (TENS) on Pain and Physical Function in Patients With Knee Osteoarthritis (ETRELKA)

Osteoarthritis, Knee

Switzerland
Eremo Hospital, Arco
University of Padova

Completed

Robot-assisted Rehabilitation of the Upper Limb in Acute and Subacute Post-stroke Patients

Stroke | Cerebrovascular Accident | Upper Extremity Paresis

Italy
AGO Research GmbH
GlaxoSmithKline

Not yet recruiting

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Primary Peritoneal Cancer | Recurrent Ovarian Cancer | Recurrent Fallopian Tube Cancer
Eli Lilly and Company
ARMO BioSciences

Terminated

Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer (Cypress 2)

Non Small Cell Lung Cancer

United States
Arno Schmidt-Trucksäss

Completed

The COmPLETE Study (COmPLETE)

Heart Failure | Aging

Switzerland
Eli Lilly and Company
ARMO BioSciences

No longer available

An Expanded Access Program for AM0010 (Pegilodecakin)

Melanoma | Renal Cell Carcinoma | Breast Cancer | Ovarian Cancer | Prostate Cancer | Non-small Cell Lung Carcinoma | Solid Tumors | Colorectal Carcinoma | Pancreatic Carcinoma
Eli Lilly and Company
ARMO BioSciences

Completed

A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants (Willow 3)

Healthy

United States
Eli Lilly and Company
ARMO BioSciences

Completed

A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) (Willow 1)

Healthy Adult Subjects

United States
Neuropsychiatric Research Institute, Fargo, North...

Withdrawn

Topiramate Augmentation in Bulimia Nervosa Partial Responders

Bulimia Nervosa

United States
Neuropsychiatric Research Institute, Fargo, North...

Withdrawn

Pramipexole for Binge Eating Disorder

Binge Eating Disorder
AEterna Zentaris
AGO Study Group

Completed

Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors

Ovarian Cancer | Endometrial Cancer

Bulgaria, Germany

Clinical Trials Sponsored by Argo Sante

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations